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THE IMMUNE RESPONSE of immuno-
competent mice against syngeneic trans-
plantable tumours is characterized by an
early positive phase followed by immuno-
suppression and progressive tumour
growth (Bertschmann et al., 1979; Kuper-
man et al., 1975). Lymphocytes capable of
lysing tumour targets in vitro can be
detected within a week of intradermal
injection of tumour cells, but become
undetectable after a further 1-2 weeks
(Takei et al., 1977). An immunogenic
tumour growing in its syngeneic host also
generates a concomitant anti-tumour im-
munity, such that the host can specifically
suppress the growth of the same tumour
implanted at a distant site (Chassoux et al.,
1977). This type of immunity declines as
the primary tumour burden increases
(Berendt & North, 1980).
The progressive decay of immune effec-
tor mechanisms during tumour growth has
been ascribed to a number of mechanisms,
including inhibition of cell-mediated im-
munity by serum-blocking factors such as
specific antibody (Hellstrom & Hellstrom,
1974) or antigen-antibody complexes
(Sjogren etal., 1973), antigenic modulation
of tumour-associated antigens (Aoki &
Johnson, 1972) and both specific and
nonspecific immunosuppression in the
tumour-bearing host due to tumour anti-
gen or tumour products (Gershon et al.,
1974; Whitney & Levy, 1975).
In this report we examined alterations
in lymphocyte profile during tumour
growth to investigate the cellular basis for
immunosuppression. Our results demon-
strate that tumour growth in a syngeneic
host generates conditions which cause the
enrichment of mature medullary thymo-
cytes bearing the phenotypic profile of
corticosteroid-resistant thymocytes, and
offer a selective advantage for the survival
of Lyt-2+ lymphocytes in the peripheral
lymphoid organs. This may be an inherent
mechanism bywhich tumour cells cause an
imbalance in lymphocyte subpopulations
and concomitant immunosuppression.
As a model system we used C57BL/6
mice carrying the syngeneic leukaemia
EL-4. Six- to eight-week-old female mice
were injected i.p. or i.m. in one hind leg
with 106 EL-4 tumour cells. Their lympo-
cyte profiles were examined by fluores-
cence-activated cell sorter (FACS) analysis
at various times after tumour injection
using monoclonal reagents against the T-
cell markers, Lyt-1, Lyt-2 and Thy-i,
against ThB which is present on all
peripheral B cells (Eckhardt & Herzen-
berg, 1980) and against Ly-6.2 which is
present on both T and B cells. Lympho-
cytes were suspended in RPMJ 1640
containing 1% fetal calf serum and 041%0
sodium azide, and aliquots of 106 cells were
stained in microtitre plates with satura-
ting levels of directly fluorescein-conju-
gated monoclonal reagents anti-Thy-I
(53-2.1), anti-Lyt-I (53-6.7), anti-Lyt-2
(53-7.3) and anti-ThB (49-h4) (Ledbetter
& Herzenberg, 1979). Monoclonal anti-Ly-
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6.2 (58.106) was kindly donated by Dr U.
Hammerling of the Sloan Kettering Can-
cer Centre. This was used in conjunction
with a fluorescein-conjugated second-step
monoclonal anti-allotype reagent anti-Igh-
la (21-74.4) (Oi & Herzenberg, 1979). The
cells were incubated first with saturating
levels of anti-Ly-6.2 for 30 min, washed
and then incubated for a further 30 min
with the second-step reagent. Fluorescence
profiles were obtained using a modified
FACS II (Becton-Dickinson FACS sys-
tems, Mountain View, Calif.) fitted with a
logarithmic amplifier. Comparative pro-
files were also obtained for thymocytes
taken 48 h after a single i.p. injection of
125 mg/kg body wt of hydrocortisone
acetate.
One week after challenge there were no
significant changes in lymphocyte profiles
in any ofthe organs examined. At the end
of the second week, however, there was
marked regression of the thymus. Vital
staining of the residual thymocyte popu-
lation with acridine orange and ethidium
bromide showed many dead cells, and
there was a corresponding reduction of
viable thymocytes to 1-2%o of normal.
These remaining thymocytes were pheno-
typically of the mature medullary type
(Fig. la, c, e). Thus, compared to a normal
thymocyte population, there was elimina-
tion of the very brightly staining Thy-I+
cells (which comprise the majority of
normal thymocytes), an increase in the
proportion of cells with high Lyt-1 anti-
genic density (not shown), a reduction in
the proportion of Lyt-2+, 3+ cells from
- 80% in normal mice to 3000 of remain-
ing thymocytes in tumour-bearing mice,
and an enrichment in the proportion ofLy-
6.2+ cells from - 100/ in normal mice up to
70°/ of the remaining thymocytes in
tumour-bearing mice. These changes are
identical to those obtained 48 h after a
single i.p. injection of 125 mg/kg hydro-
cortisone acetate (Fig. Ib, d, f). Micklem et
al. (1980) note similar changes in the
thymus of corticosteroid-treated mice.
The spleens of the tumour-bearing mice
were greatly enlarged but contained few
lymphocyte. Analysis of the splenocytes
by size and staining profiles revealed a
population of large cells which were Lyt-
1-, Lyt-2-, Thy-l- and ThB-, indicating
their non-T non-B phenotype. They were
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FIG. 1.- FACS analysis of tliymocytes from
normal ( . ) and tumour bearing ( )
C57BL/6 mice stained with (a) anti-Thy-1,
(c) anti-Lyt-2 and (e) anti-Ly-6.2. Com-
parative staining profiles for thymocytes
obtained 48 h after a single i.p. injection of
125 mg/kg of hydrocortisone acetate are
slbown in (b) for anti-Thy-1, (d) anti-Lyt-2
andl (f) anti-Ly-6.2. In (e) the profile for
second step alone has been omitted because
it almost entirely coincides with the normal
staining profile, there being only 1°/ Ly-
6.2+ cells in the thymus of normal C57BL/6
mice. The dotted line in (f) ( ) represents
the fluorescence of cells stained with
second step alone. In all cases, auto-
fluorescence of unstained cells did not
exceed a fluorescence intensity of 1 on the
logarithmic scale. The profiles show7n are for
mice injected i.p.; identical results were
obtained from the mice injected i.m.
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FIG. 2.-FACS analysis of splenocytes from
normal (- ..... ) and tumour-bearing ( ~)
mice stained with (a) anti-Thy-1, (b) anti-
LYt-2 and (c) anti-ThB. The autofluores-
cence profiles of unstained cells have been
omitted for clarity, but did not exceed 1-3
units on the arbitraryfluorescence intensity
(loglo) scale. Thus the positive-staining
populations are those from 1-3 units up-
wards in (b) and (c). In (a) the positive
populations are considered to begin at 1-7
units; the Thy antigen is shed in culture
andnonspecifically binds to B cells, causing
the negative population to stain slightly
more brightly than autofluorescence (J.
Ledbetter, unpublished observations).
also Ly-6.2- and thus not EL-4 tumour
cells, since all tumours, whether derived
from ascites or from solid i.m. tumour,
stained brightly for Ly-6.2. These cells are
currently under investigation. Less than
10% of viable splenocytes were in the size
range of lymphocytes. Amongst these, the
proportion of Lyt-2+ cells remained at
normal level (Fig. 2). However, the
proportion ofT cells was reduced from the
normal level of30%/ in C57BL/6 mice to a
mean ofI11% in the i.p. injected group and
14% in the i.m. injected group. Thus,
although there was a marked reduction in
lymphocyte number of all T-cell subsets,
the Lyt-2+ cells were relatively resistant,
so ofthe remaining T cells 86% were Lyt-
2+, compared to 40% in the normal mouse
(Fig. 2; Table; and cf. Ledbetter et al.,
1980).
TABLE.-Percentage ofThy-I+ lymphocytes
and % ofLyt-2+cells oftotalT cells in the
spleen ofcontrol and tumour-bearing mice
2 weeks after tumour injection
Surface phenotype
%Thy-1+ cells
%Lyt-2+ cells of
T cells
Control
30+2-9
43+2-1
Tumour-bearing
i.p. i.m.
11+2-5 14+4-0
87+5-7 86+2-8
Population sizes were derived from integration of
the FACS curves and are expressed as the means
+ s.d. of 5 observations.
The proportion of B cells was also
reduced from 55-60% in normal mice to
35-40% in the tumour-bearing mice (Fig.
2c). Similar population changes were noted
in the lymph nodes. T-cell numbers were
reduced to 5-10% ofnormal, most remain-
ing T cells being Lyt-2+.
These observations provide several pos-
sible explanations for the immunosuppres-
sion which is known to develop during
tumourprogression. Previous workershave
demonstrated an initial positive immune
response to EL-4 by C57BL/6 mice 1 week
after tumour challenge (Apffel et al., 1966;
Kemp et al., 1973). At this time we were
unable to detect any changes in the overall
lymphocyte populations in the spleen,
lymph nodes and thymus, which is con-
sistent with an uncompromised immune
response. Later, when the immune re-
sponse is known to be diminished, we
detected characteristic selective lympho-
cytolysis. This, ofitself, would be expected
to diminish the potential immune rsponse
and, since at this time of tumour growth
almost all lymphocytes are of the Lyt-2+
subclass, these could be immuno-incom-
petent due to lack of Lyt-l+, 2- helper
cells. Recently, the nonreactivity of corti-
cal Lyt-2+ thymocytes in developing into
cytotoxic T cells was shown to be due to
lack of Lyt-l+, 2- helper cells rather than
inherent immuno-incompetence (Wagner
et al., 1980). Our data are also consistent
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with the considerable volume of evidence
that immunogenic tumours induce the
generation of suppressor cells in function-
ally dominant numbers (Perry et al,. 1978;
Kuperman et al., 1975) though as yet we
have not characterized the Lyt-2+ popula-
tion found in our experiments as
suppressive. However, perhaps the most
interesting observation derived from this
work is the similarity between the effects
of tumour growth and the administration
ofa pharmacological dose of corticosteroid
on both the thymus (Fig. 1) and peripheral
lymphoid organs. Corticosteroid is used as
a nonspecific immunosuppressant, though
the mechanism ofits action is unclear. We
have recently shown that Lyt-2+ cells are
selectively resistant to corticosteroid, both
in peripheral lymphoid organs (Rogers &
Matossian-Rogers, 1982) and also within
the putative mature thymocyte popula-
tion (Rogers & Matossian-Rogers, 1981).
There was a dose-related increase of the
Lyt-2+ splenic population from 30% up to
60% of total remaining T lymphocytes
48 h after a single injection of hydro-
cortisone acetate in doses ranging from
62-5 to 500 mg/kg. In the thymus, the
lowest dose ofsteroid caused a reduction of
the Lyt-2+ population from 80 to 30%;
thereafter, there was a dose-related
increase of Lyt-2+ cells. Thus not only are
the thymocyte profiles of tumour-bearing
mice similar to steroid-treated animals
(Fig. 1) but the reduction in lymphocyte
numbers and relative increase in Lyt-2+
cells in peripheral lymphoid organs of
tumour-bearing mice (Fig. 2a, b) are also
characteristic of steroid treatment. This
suggests that the mechanism of action in
both cases may be similar, and that
tumours may thereby have a marked non-
specific immunosuppressant role.
One further interesting feature from this
work was the high percentage of null cells
that we found in the spleen and lymph
node. The spleens of the tumour-bearing
mice were enlarged 2 weeks after tumour
injection; most of the splenocytes were
large null cells outside the size range of
lymphocytes. Furthermore, of those cells
within lymphocyte size range, 45% were
null-staining cells. We do not know the
origin or function ofthese cells but in view
oftheir prevalence we are currently trying
to determine their significance.
Although this workwas performed using
the C57BL/6, EL-4 model, we have noted
similar thymic regression in many other
host-tumour combinations and have con-
firmed the selection of mature thymocytes
by FACS analysis in DBA/2 mice given the
L5178Y tumour.
We wish to thank Professor L. A. Herzenberg in
whose laboratory the work was performed and Dr J.
Ledbetter who kindly donated the monoclonal
reagents. The work was partly supported by the
Cancer Research Campaign.
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